These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. Hobeika L; Self SE; Velez JC BMC Nephrol; 2014 Sep; 15():156. PubMed ID: 25267524 [TBL] [Abstract][Full Text] [Related]
4. Microangiopathy in multiple myeloma: a case of carfilzomib-induced secondary thrombotic microangiopathy successfully treated with plasma exchange and complement inhibition. Catanese L; Link K; Rupprecht H BMC Nephrol; 2023 Jun; 24(1):179. PubMed ID: 37337151 [TBL] [Abstract][Full Text] [Related]
5. Complement as the enabler of carfilzomib-induced thrombotic microangiopathy. Blasco M; Martínez-Roca A; Rodríguez-Lobato LG; Garcia-Herrera A; Rosiñol L; Castro P; Fernández S; Quintana LF; Cibeira MT; Bladé J; Fernández de Larrea C; Tovar N; Jimenez R; Poch E; Guillen E; Campistol JM; Carreras E; Diaz-Ricart M; Palomo M Br J Haematol; 2021 Apr; 193(1):181-187. PubMed ID: 32469083 [TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibitor associated thrombotic microangiopathy. Yui JC; Van Keer J; Weiss BM; Waxman AJ; Palmer MB; D'Agati VD; Kastritis E; Dimopoulos MA; Vij R; Bansal D; Dingli D; Nasr SH; Leung N Am J Hematol; 2016 Sep; 91(9):E348-52. PubMed ID: 27286661 [TBL] [Abstract][Full Text] [Related]
10. Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature. Monteith BE; Venner CP; Reece DE; Kew AK; Lalancette M; Garland JS; Shepherd LE; Pater JL; Hay AE Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e791-e800. PubMed ID: 32807717 [TBL] [Abstract][Full Text] [Related]
11. Clinical features, treatment, and outcomes of patients with carfilzomib induced thrombotic microangiopathy. Fang W; Sun W; Fang W; Zhao S; Wang C Int Immunopharmacol; 2024 Jun; 134():112178. PubMed ID: 38728883 [TBL] [Abstract][Full Text] [Related]
12. Carfilzomib-induced thrombotic microangiopathy. A case report. Scheggi V; Merilli I; Cesaroni E; Alterini B J Oncol Pharm Pract; 2022 Apr; 28(3):754-758. PubMed ID: 34904466 [TBL] [Abstract][Full Text] [Related]
13. Carfilzomib: A cause of drug associated thrombotic microangiopathy. Qaqish I; Schlam IM; Chakkera HA; Fonseca R; Adamski J Transfus Apher Sci; 2016 Jun; 54(3):401-4. PubMed ID: 27017313 [TBL] [Abstract][Full Text] [Related]
14. A review of thrombotic microangiopathies in multiple myeloma. Portuguese AJ; Gleber C; Passero FC; Lipe B Leuk Res; 2019 Oct; 85():106195. PubMed ID: 31404728 [TBL] [Abstract][Full Text] [Related]
15. Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study. Camilleri M; Cuadrado M; Phillips E; Wilson W; Jenner R; Pang G; Kamora S; Streetly M; Popat R; Bygrave C; Owen R; Cavenagh J; Chapman M; Sive J; Eccersley L; Sheaff M; Benjamin R; Ramasamy K; Cook G; Virchis A; Chavda SJ; Clifton-Hadley L; Scully MA; Yong K Br J Haematol; 2021 May; 193(4):750-760. PubMed ID: 33650100 [TBL] [Abstract][Full Text] [Related]
16. High dose carfilzomib proteasome inhibition induces anemia by oxidative hemolysis: A case series of 8 patients from a single centre. Rajagopal R; Bennett R; Liang J; Royle G Am J Hematol; 2019 Aug; 94(8):E215-E216. PubMed ID: 31066096 [No Abstract] [Full Text] [Related]
17. Carfilzomib-induced thrombotic microangiopathy is underestimated in clinical practice: A report of five patients and literature review. Terao T; Tsushima T; Miura D; Ikeda D; Fukumoto A; Kuzume A; Tabata R; Narita K; Takeuchi M; Matsue K Leuk Lymphoma; 2022 May; 63(5):1102-1110. PubMed ID: 35373680 [TBL] [Abstract][Full Text] [Related]
18. Carfilzomib-induced thrombotic microangiopathy (TMA): an under-recognised spectrum of disease from microangiopathic haemolysis to subclinical TMA. Ponraj R; Bryant A; Dunlop L; Range H; Cobrador C; Ling S; Hsu D Blood Cancer J; 2023 Jul; 13(1):113. PubMed ID: 37495597 [No Abstract] [Full Text] [Related]
19. Thrombotic microangiopathy after carfilzomib in a very young myeloma patient. Jeyaraman P; Borah P; Singh A; Chhabra GD; Khullar D; Dayal N; Naithani R Blood Cells Mol Dis; 2020 Mar; 81():102400. PubMed ID: 31887694 [No Abstract] [Full Text] [Related]
20. [Thrombotic microangiopathy with gastrointestinal hemorrhage during carfilzomib therapy for multiple myeloma]. Matsumoto S; Takahashi H; Hamada T; Miura K; Nakagwa M; Kurihara K; Endo T; Koike T; Iizuka K; Iriyama N; Nakayama T; Hatta Y; Nakamura H Rinsho Ketsueki; 2023; 64(4):255-259. PubMed ID: 37121768 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]